Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National Test-Negative Design Case-Control Study

Eleftheria Vasileiou* (Corresponding Author), Aziz Sheikh, Chris C Butler, Chris Robertson, Kimberley Kavanagh, Tanya Englishby, Nazir I Lone, Beatrix von Wissmann, Jim McMenamin, Lewis D Ritchie, Jürgen Schwarze, Rory Gunson, Colin R Simpson

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Influenza infection is an important trigger of asthma attacks. Influenza vaccination has the potential to reduce the incidence of influenza in people with asthma, but uptake remains persistently low, partially reflecting concerns about vaccine effectiveness (VE).

METHODS: We conducted a test-negative design case-control study to estimate the effectiveness of influenza vaccine in children and adults with asthma in Scotland over six influenza seasons (2010/11 to 2015/16). We used individual patient level data from 223 primary care practices which yielded 1,830,772 patient-years of data, which were linked with hospital and virological (n=5,910 swabs) data.

RESULTS: Vaccination was associated with an overall 55.0% (95% confidence interval (CI): 45.8-62.7) reduction in the risk of a laboratory-confirmed influenza infection in people with asthma over the six seasons. There was substantial variation in VE between seasons, influenza strains and age groups. The highest VE (76.1%; 95% CI: 55.6-87.1) was found in 2010/11 season where the A(H1N1) strain dominated and there was a good antigenic vaccine match. High protection was observed against A(H1N1) (e.g. 2010/11: 70.7%; 95%CI: 32.5-87.3) and B strains (e.g. 2010/11: 83.2%; 95%CI: 44.3-94.9), but there was lower protection for the A(H3N2) strain (e.g. 2014/15: 26.4%; 95%CI: -12.0-51.6). The highest VE against all viral strains was observed in adults aged 18-54 years (57.0%; 95%CI: 42.3-68.0).

CONCLUSION: Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in people asthma across all six seasons. Strategies to boost influenza vaccine uptake has the potential to substantially reduce influenza triggered asthma attacks.

Original languageEnglish
Number of pages11
JournalClinical Infectious Diseases
Early online date5 Nov 2019
DOIs
Publication statusE-pub ahead of print - 5 Nov 2019

Fingerprint

Influenza Vaccines
Human Influenza
Case-Control Studies
Asthma
Confidence Intervals
Vaccines
Vaccination
Scotland
Risk Reduction Behavior
Infection
Primary Health Care
Age Groups
Incidence

Keywords

  • influenza
  • vaccination
  • asthma
  • laboratory-confirmed influenza

Cite this

Seasonal Influenza Vaccine Effectiveness in People With Asthma : A National Test-Negative Design Case-Control Study . / Vasileiou, Eleftheria (Corresponding Author); Sheikh, Aziz; Butler, Chris C; Robertson, Chris; Kavanagh, Kimberley; Englishby, Tanya; Lone, Nazir I; von Wissmann, Beatrix; McMenamin, Jim; Ritchie, Lewis D; Schwarze, Jürgen; Gunson, Rory; Simpson, Colin R.

In: Clinical Infectious Diseases, 05.11.2019.

Research output: Contribution to journalArticle

Vasileiou, E, Sheikh, A, Butler, CC, Robertson, C, Kavanagh, K, Englishby, T, Lone, NI, von Wissmann, B, McMenamin, J, Ritchie, LD, Schwarze, J, Gunson, R & Simpson, CR 2019, 'Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National Test-Negative Design Case-Control Study ', Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciz1086
Vasileiou, Eleftheria ; Sheikh, Aziz ; Butler, Chris C ; Robertson, Chris ; Kavanagh, Kimberley ; Englishby, Tanya ; Lone, Nazir I ; von Wissmann, Beatrix ; McMenamin, Jim ; Ritchie, Lewis D ; Schwarze, Jürgen ; Gunson, Rory ; Simpson, Colin R. / Seasonal Influenza Vaccine Effectiveness in People With Asthma : A National Test-Negative Design Case-Control Study . In: Clinical Infectious Diseases. 2019.
@article{c8ac881977604f689664a0e34cb285a9,
title = "Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National Test-Negative Design Case-Control Study",
abstract = "BACKGROUND: Influenza infection is an important trigger of asthma attacks. Influenza vaccination has the potential to reduce the incidence of influenza in people with asthma, but uptake remains persistently low, partially reflecting concerns about vaccine effectiveness (VE).METHODS: We conducted a test-negative design case-control study to estimate the effectiveness of influenza vaccine in children and adults with asthma in Scotland over six influenza seasons (2010/11 to 2015/16). We used individual patient level data from 223 primary care practices which yielded 1,830,772 patient-years of data, which were linked with hospital and virological (n=5,910 swabs) data.RESULTS: Vaccination was associated with an overall 55.0{\%} (95{\%} confidence interval (CI): 45.8-62.7) reduction in the risk of a laboratory-confirmed influenza infection in people with asthma over the six seasons. There was substantial variation in VE between seasons, influenza strains and age groups. The highest VE (76.1{\%}; 95{\%} CI: 55.6-87.1) was found in 2010/11 season where the A(H1N1) strain dominated and there was a good antigenic vaccine match. High protection was observed against A(H1N1) (e.g. 2010/11: 70.7{\%}; 95{\%}CI: 32.5-87.3) and B strains (e.g. 2010/11: 83.2{\%}; 95{\%}CI: 44.3-94.9), but there was lower protection for the A(H3N2) strain (e.g. 2014/15: 26.4{\%}; 95{\%}CI: -12.0-51.6). The highest VE against all viral strains was observed in adults aged 18-54 years (57.0{\%}; 95{\%}CI: 42.3-68.0).CONCLUSION: Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in people asthma across all six seasons. Strategies to boost influenza vaccine uptake has the potential to substantially reduce influenza triggered asthma attacks.",
keywords = "influenza, vaccination, asthma, laboratory-confirmed influenza",
author = "Eleftheria Vasileiou and Aziz Sheikh and Butler, {Chris C} and Chris Robertson and Kimberley Kavanagh and Tanya Englishby and Lone, {Nazir I} and {von Wissmann}, Beatrix and Jim McMenamin and Ritchie, {Lewis D} and J{\"u}rgen Schwarze and Rory Gunson and Simpson, {Colin R}",
note = "Financial support. The work was funded by the Chief Scientist Office of the Scottish Government under the grant (AUKCAR/14/03) and the NIHR–Health Technology Assessment (HTA) Programme (13/34/14) for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. As principal investigator, C. R. S. received a grant for the SIVE-II project from the NIHR HTA. This work was carried out with the support of the Asthma UK Centre for Applied Research (AUK-AC-2012-01), the Farr Institute (MR/M501633/2), Health Data Research UK (an initiative funded by UK Research and Innovation, Department of Health and Social Care England and the devolved administrations and leading medical research charities), the European Union’s Horizon 2020 research and innovation programme (under grant agreement No 634446) and European Centre for Disease Prevention and Control (Influenza-Monitoring Vaccine Effectiveness). Acknowledgments. The authors thank and acknowledge all colleagues at the Asthma UK Centre for Applied Research for their support in this study. Disclaimer. The funding bodies had no role in the design of the study, review process, analysis, interpretation, or reporting of data. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Health Technology Assessment Programme, National Institute for Health Research (NIHR), National Health Service, or the Department of Health. Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.",
year = "2019",
month = "11",
day = "5",
doi = "10.1093/cid/ciz1086",
language = "English",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Seasonal Influenza Vaccine Effectiveness in People With Asthma

T2 - A National Test-Negative Design Case-Control Study

AU - Vasileiou, Eleftheria

AU - Sheikh, Aziz

AU - Butler, Chris C

AU - Robertson, Chris

AU - Kavanagh, Kimberley

AU - Englishby, Tanya

AU - Lone, Nazir I

AU - von Wissmann, Beatrix

AU - McMenamin, Jim

AU - Ritchie, Lewis D

AU - Schwarze, Jürgen

AU - Gunson, Rory

AU - Simpson, Colin R

N1 - Financial support. The work was funded by the Chief Scientist Office of the Scottish Government under the grant (AUKCAR/14/03) and the NIHR–Health Technology Assessment (HTA) Programme (13/34/14) for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. As principal investigator, C. R. S. received a grant for the SIVE-II project from the NIHR HTA. This work was carried out with the support of the Asthma UK Centre for Applied Research (AUK-AC-2012-01), the Farr Institute (MR/M501633/2), Health Data Research UK (an initiative funded by UK Research and Innovation, Department of Health and Social Care England and the devolved administrations and leading medical research charities), the European Union’s Horizon 2020 research and innovation programme (under grant agreement No 634446) and European Centre for Disease Prevention and Control (Influenza-Monitoring Vaccine Effectiveness). Acknowledgments. The authors thank and acknowledge all colleagues at the Asthma UK Centre for Applied Research for their support in this study. Disclaimer. The funding bodies had no role in the design of the study, review process, analysis, interpretation, or reporting of data. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Health Technology Assessment Programme, National Institute for Health Research (NIHR), National Health Service, or the Department of Health. Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

PY - 2019/11/5

Y1 - 2019/11/5

N2 - BACKGROUND: Influenza infection is an important trigger of asthma attacks. Influenza vaccination has the potential to reduce the incidence of influenza in people with asthma, but uptake remains persistently low, partially reflecting concerns about vaccine effectiveness (VE).METHODS: We conducted a test-negative design case-control study to estimate the effectiveness of influenza vaccine in children and adults with asthma in Scotland over six influenza seasons (2010/11 to 2015/16). We used individual patient level data from 223 primary care practices which yielded 1,830,772 patient-years of data, which were linked with hospital and virological (n=5,910 swabs) data.RESULTS: Vaccination was associated with an overall 55.0% (95% confidence interval (CI): 45.8-62.7) reduction in the risk of a laboratory-confirmed influenza infection in people with asthma over the six seasons. There was substantial variation in VE between seasons, influenza strains and age groups. The highest VE (76.1%; 95% CI: 55.6-87.1) was found in 2010/11 season where the A(H1N1) strain dominated and there was a good antigenic vaccine match. High protection was observed against A(H1N1) (e.g. 2010/11: 70.7%; 95%CI: 32.5-87.3) and B strains (e.g. 2010/11: 83.2%; 95%CI: 44.3-94.9), but there was lower protection for the A(H3N2) strain (e.g. 2014/15: 26.4%; 95%CI: -12.0-51.6). The highest VE against all viral strains was observed in adults aged 18-54 years (57.0%; 95%CI: 42.3-68.0).CONCLUSION: Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in people asthma across all six seasons. Strategies to boost influenza vaccine uptake has the potential to substantially reduce influenza triggered asthma attacks.

AB - BACKGROUND: Influenza infection is an important trigger of asthma attacks. Influenza vaccination has the potential to reduce the incidence of influenza in people with asthma, but uptake remains persistently low, partially reflecting concerns about vaccine effectiveness (VE).METHODS: We conducted a test-negative design case-control study to estimate the effectiveness of influenza vaccine in children and adults with asthma in Scotland over six influenza seasons (2010/11 to 2015/16). We used individual patient level data from 223 primary care practices which yielded 1,830,772 patient-years of data, which were linked with hospital and virological (n=5,910 swabs) data.RESULTS: Vaccination was associated with an overall 55.0% (95% confidence interval (CI): 45.8-62.7) reduction in the risk of a laboratory-confirmed influenza infection in people with asthma over the six seasons. There was substantial variation in VE between seasons, influenza strains and age groups. The highest VE (76.1%; 95% CI: 55.6-87.1) was found in 2010/11 season where the A(H1N1) strain dominated and there was a good antigenic vaccine match. High protection was observed against A(H1N1) (e.g. 2010/11: 70.7%; 95%CI: 32.5-87.3) and B strains (e.g. 2010/11: 83.2%; 95%CI: 44.3-94.9), but there was lower protection for the A(H3N2) strain (e.g. 2014/15: 26.4%; 95%CI: -12.0-51.6). The highest VE against all viral strains was observed in adults aged 18-54 years (57.0%; 95%CI: 42.3-68.0).CONCLUSION: Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in people asthma across all six seasons. Strategies to boost influenza vaccine uptake has the potential to substantially reduce influenza triggered asthma attacks.

KW - influenza

KW - vaccination

KW - asthma

KW - laboratory-confirmed influenza

U2 - 10.1093/cid/ciz1086

DO - 10.1093/cid/ciz1086

M3 - Article

C2 - 31688921

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -